Despite the promising clinical potential of Asundexian observed in phase 1 and 2 trials, the OCEANIC-AF (A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat [Atrial Fibrillation], and at Risk for Stroke) (NCT05643573) phase 3 trial was recently terminated early because of inferior efficacy in comparison to the activated factor X inhibitor Apixaban for prevention of stroke and systemic embolism in patients with atrial fibrillation.44 Here, F10 is linked to stroke disorder.